◎ Sugi Atlas

Atlas / Drug / Ropivacaine

Ropivacaine

drug
On this page

Also known as RopivacainaRopivicaineTLC-590Tlc590SID26758019levoropivacaine(S)-RopivacaineRopivacaine HCl

Summary

Ropivacaine (CHEMBL1077896) is an approved small-molecule local anaesthetic (ATC N01BB09) targeting SCN5A; indicated across 30 conditions including breast neoplasm and hypotensive disorder.

At a glance

  • Status: Approved (max clinical phase 4)
  • Modality: Small molecule
  • ATC class: N01BB09
  • Targets: 1 (SCN5A)
  • Indications: 30 conditions
  • Clinical trials: 775
  • Chemistry: 274.4 Da · C17H26N2O

Identifiers

Drug identity and classification

FieldValue
ChEMBL IDCHEMBL1077896
NameRopivacaine
TypeSmall molecule
Max phase4
FDA approvedyes
PubChem CID175805
ChEBICHEBI:8890
ATCN01BB09
Molecular formulaC17H26N2O
Molecular weight274.4
InChIKeyZKMNUMMKYBVTFN-HNNXBMFYSA-N

SMILES: CCCN1CCCC[C@H]1C(=O)NC2=C(C=CC=C2C)C

IUPAC name: (2S)-N-(2,6-dimethylphenyl)-1-propylpiperidine-2-carboxamide

ChEBI definition: A piperidinecarboxamide-based amide-type local anaesthetic (amide caine) in which (S)-N-propylpipecolic acid and 2,6-dimethylaniline are combined to form the amide bond.

Pharmacological roles (ChEBI): local anaesthetic.

Also known as: Ropivacaina, Ropivacaine, Ropivicaine, TLC-590, Tlc590, TLC590, SID26758019, levoropivacaine, ropivacaine, ROPIVACAINE, (S)-Ropivacaine, Ropivacaine HCl

Parent form; salt/anhydrous children: CHEMBL1889140

Patent coverage: 4,675 distinct patent families (17,078 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

GeneTargetActionpAffinityCancer dependencyUniProt
SCN5ANav1.5Pore blocker3.490.2%Q14524

Broader ChEMBL bioactivity targets: 2 (assay-derived). Sample: Prelamin-A/C, Potassium channel subfamily K member 3.

Bioactivity

ChEMBL activities: 1 potent at pChembl ≥ 5 of 2 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

TargetpChemblTypeValueUnitActivity ID
LMNA5.6Potency2512nMCHEMBL_ACT_3635483

Target pathways

Aggregated over 1 target gene(s): SCN5A.

Top Reactome pathways

8 total, by targets touching each:

PathwayTargetsGenes
Developmental Biology1SCN5A
L1CAM interactions1SCN5A
Muscle contraction1SCN5A
Axon guidance1SCN5A
Interaction between L1 and Ankyrins1SCN5A
Cardiac conduction1SCN5A
Phase 0 - rapid depolarisation1SCN5A
Nervous system development1SCN5A

Dominant GO biological processes

GO termTargets
regulation of heart rate1
cardiac conduction system development1
cardiac ventricle development1
brainstem development1
sodium ion transport1
positive regulation of sodium ion transport1
response to denervation involved in regulation of muscle adaptation1
telencephalon development1
cerebellum development1
sodium ion transmembrane transport1
odontogenesis of dentin-containing tooth1
positive regulation of action potential1
positive regulation of epithelial cell proliferation1
membrane depolarization1
cardiac muscle contraction1

Indications & clinical

Indications

30 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

IndicationTrial phaseMONDOEFO
breast neoplasm3MONDO:0021100EFO:0003869
hypotensive disorder3MONDO:0005468EFO:0005251
ovarian cyst3MONDO:0003282HP:0000138
palsy3MONDO:0006496HP:0003470
gastric neoplasm3MONDO:0021085MONDO:0001056
ovarian cancer3MONDO:0008170MONDO:0008170
osteoarthritis, knee3MONDO:0005416EFO:0004616
male reproductive organ cancer3MONDO:0005836EFO:0007355
bone fracture3MONDO:0005315EFO:0003931
pain agnosia3MONDO:0000675EFO:1001484
appendicitis2MONDO:0005649EFO:0007149
rotator cuff syndrome2MONDO:0007028EFO:1001250
post-traumatic stress disorder2MONDO:0005146EFO:0001358
arthropathy2MONDO:0006816HP:0003040
leiomyoma2MONDO:0001572MONDO:0001572
osteoarthritis2MONDO:0005178MONDO:0005178
neoplasm2MONDO:0005070MONDO:0004992
plantar fasciitis1MONDO:0004833EFO:1001909
sinusitis1MONDO:0005961EFO:0007486

11 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 775.

Phase distribution

PhaseTrials
PHASE4304
Not specified276
PHASE388
PHASE250
PHASE2/PHASE321
PHASE115
EARLY_PHASE112
PHASE1/PHASE29

Top trials by phase / activity

NCTPhaseStatusTitle
NCT03230565PHASE4RECRUITINGContinuous Infusions vs Scheduled Bolus Infusions
NCT03632044PHASE4ACTIVE_NOT_RECRUITINGEvaluation of Trigeminal Nerve Blockade
NCT03796572PHASE4RECRUITINGRegional Blocks for Lateral Condyle Fractures
NCT04130464PHASE4RECRUITINGIntraperitoneal Infusion of Analgesic for Postoperative Pain Management
NCT05323175PHASE4ACTIVE_NOT_RECRUITINGErector Spinae Plane (ESP) Block for Renal Colic
NCT05488847PHASE4ACTIVE_NOT_RECRUITINGOpioid-Free Pain Protocol After Shoulder Arthroplasty
NCT05544721PHASE4ENROLLING_BY_INVITATIONA Study of Paravertebral Block in Thoracic Outlet Syndrome
NCT05642026PHASE4RECRUITINGINTERCOSTAL NERVE BLOCK: Efficacy of CINB for Patients With Multiple Rib Fractures
NCT05972018PHASE4RECRUITINGLiposomal Bupivacaine/Bupivacaine in Rectus Sheath Blocks Versus Ropivacaine in Rectus Sheath Blocks And Catheters
NCT06054750PHASE4NOT_YET_RECRUITINGTesting Regional anesthesia Techniques For Up And Early Discharge Following Knee arthroplasty - a Feasibility Study
NCT06189781PHASE4RECRUITINGPain Injection Versus Epidural Anesthesia for Hip Surgery in Pediatric Patients With Cerebral Palsy
NCT06406010PHASE4RECRUITINGInvestigating the Effect of Pericapsular Nerve Group (PENG) Block on Postoperative Pain After Peri-acetabular Osteotomy
NCT06565910PHASE4RECRUITINGBupivacaine Liposome Plus Bupivacaine or Ropivacaine for Pericapsular Nerve Group Block in Hip Arthroplasty (PENG)
NCT06636578PHASE4RECRUITINGDexmedetomidine Ropivacaine Versus Plain Ropivacaine in Bilateral Pectoralis Nerve (PECS) Block
NCT06711679PHASE4ENROLLING_BY_INVITATIONExploring the Minimum Effective Concentration and Volume of Ropivacaine for Sacral Plexus Anesthesia
NCT06981949PHASE4NOT_YET_RECRUITINGAddition of Dexmedetomidine to Ropivacaine in Bilateral Erector Spinae Plane Block in Patients Undergoing Coronary Artery Bypass Surgery
NCT07006168PHASE4RECRUITINGEffects Of Intra-Operative Intra-Articular Cocktail Injection In Patella Open Reduction And Internal Fixation
NCT07023094PHASE4RECRUITINGPENG With LFCB vs. ESP Blocks for Pediatric Hip Surgery
NCT07116343PHASE4RECRUITINGIntrapleural Ropivacaine Infusion in Cardiac Surgery
NCT07176065PHASE4NOT_YET_RECRUITINGDexmedetomidine as an Adjunct to Periarticular Ropivacaine in Total Knee Replacement: A Pilot Randomised Controlled Trial
NCT07180979PHASE4RECRUITINGPENG vs L-ESPB With S-ESPB for Analgesia in Total Hip Arthroplasty
NCT07216586PHASE4NOT_YET_RECRUITINGZynrelef Versus Adductor Canal Block
NCT07259772PHASE4ACTIVE_NOT_RECRUITINGAnesthetic Effect of Ropivacaine on Local Infiltration Anesthesia in Arteriovenous Fistula Surgery
NCT07316166PHASE4RECRUITINGSuprainguinal Fascia Iliaca Block With vs Without Dexmedetomidine
NCT07349810PHASE4RECRUITINGPost Operative Infusion Pump Pain Study
NCT00421967PHASE4TERMINATEDPostoperative Analgesia After Total Knee Arthroplasty
NCT00523289PHASE4UNKNOWNCardiovascular Safety Research: Bupivacaine With Vasoconstrictor Versus Ropivacaine in Brachial Plexus Block
NCT00529425PHASE4COMPLETEDPostoperative Analgesia With Local Infiltration After Femoral Neck Fracture
NCT00552864PHASE4COMPLETEDComparison of Ropivacaine and Levobupivacaine in High Thoracic Epidural Anesthesia
NCT00562627PHASE4COMPLETEDEfficacy of Multimodal Peri- and Intraarticular Drug Injections in Total Knee Arthroplasty
NCT00567450PHASE4COMPLETEDRopivacaine Versus Ropivacaine Plus Mepivacaine for Sciatic Block
NCT00620828PHASE4COMPLETEDThe Role of Intra-Operative Intracapsular Blocks in Post-Operative Pain Management Following Total Knee Arthroplasty
NCT00638508PHASE4COMPLETEDON-Q Pump Infusion of Ketorolac and Ropivacaine at the Wound Site for Postoperative Pain Management
NCT00678314PHASE4COMPLETEDPatient Controlled Regional Analgesia Following Carpal Tunnel Release: A Double-Blind Study Using Distal Perineural Catheters
NCT00702416PHASE4COMPLETEDUltrasound Guidance for Interscalene Brachial Plexus Block
NCT00724035PHASE4COMPLETEDUltrasound-Guided Axillary or Infraclavicular Nerve Block for Upper Limb Surgery
NCT00768456PHASE4COMPLETEDLocal Infiltration Analgesia With Ropivacaine Versus Placebo in Vaginal Hysterectomy: a Randomized, Double-Blind Study
NCT00769054PHASE4COMPLETEDLocal Infiltration Analgesia With Ropivacaine in Posterior Vaginal Wall Prolapse:a Randomized, Double-Blind Study
NCT00771459PHASE4COMPLETEDLocal Infiltration Analgesia in Major Spine Surgery With Ropivacaine Versus Placebo
NCT00771862PHASE4TERMINATEDPrevention of Phantom Limb and Stump Pain Using Ambulatory Continuous Peripheral Nerve Blocks: A Pilot Study

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

126 molecules share ≥1 primary target. Top 60 by shared-target count:

MoleculeSourceStatusShared targets
PALIPERIDONEChEMBL + PubChemPhase 4 (approved)SCN5A
AMIODARONEChEMBLPhase 4 (approved)SCN5A
AMITRIPTYLINEChEMBLPhase 4 (approved)SCN5A
AMLODIPINEChEMBLPhase 4 (approved)SCN5A
ASENAPINEChEMBLPhase 4 (approved)SCN5A
ASTEMIZOLEChEMBLPhase 4 (approved)SCN5A
BAZEDOXIFENEChEMBLPhase 4 (approved)SCN5A
BENZONATATEChEMBLPhase 4 (approved)SCN5A
BEPRIDILChEMBLPhase 4 (approved)SCN5A
CANDESARTAN CILEXETILChEMBLPhase 4 (approved)SCN5A
CARBAMAZEPINEChEMBLPhase 4 (approved)SCN5A
CARVEDILOLChEMBLPhase 4 (approved)SCN5A
CHLORPROMAZINEChEMBLPhase 4 (approved)SCN5A
CISAPRIDEChEMBLPhase 4 (approved)SCN5A
CLEMASTINEChEMBLPhase 4 (approved)SCN5A
CLOZAPINEChEMBLPhase 4 (approved)SCN5A
DABIGATRAN ETEXILATEChEMBLPhase 4 (approved)SCN5A
DARIFENACINChEMBLPhase 4 (approved)SCN5A
DARUNAVIRChEMBLPhase 4 (approved)SCN5A
DASATINIBChEMBLPhase 4 (approved)SCN5A
DEFERASIROXChEMBLPhase 4 (approved)SCN5A
DESIPRAMINEChEMBLPhase 4 (approved)SCN5A
DIBUCAINEChEMBLPhase 4 (approved)SCN5A
DILTIAZEMChEMBLPhase 4 (approved)SCN5A
DIPHENHYDRAMINEChEMBLPhase 4 (approved)SCN5A
DOMPERIDONEChEMBLPhase 4 (approved)SCN5A
DROPERIDOLChEMBLPhase 4 (approved)SCN5A
DULOXETINEChEMBLPhase 4 (approved)SCN5A
ETIDOCAINEChEMBLPhase 4 (approved)SCN5A
FEDRATINIBChEMBLPhase 4 (approved)SCN5A
FELODIPINEChEMBLPhase 4 (approved)SCN5A
FLECAINIDEChEMBLPhase 4 (approved)SCN5A
FLUPHENAZINEChEMBLPhase 4 (approved)SCN5A
FLUVOXAMINEChEMBLPhase 4 (approved)SCN5A
HALOPERIDOLChEMBLPhase 4 (approved)SCN5A
IMIPRAMINEChEMBLPhase 4 (approved)SCN5A
ISRADIPINEChEMBLPhase 4 (approved)SCN5A
LAMOTRIGINEChEMBLPhase 4 (approved)SCN5A
LETERMOVIRChEMBLPhase 4 (approved)SCN5A
LIDOCAINEChEMBLPhase 4 (approved)SCN5A
LOPERAMIDEChEMBLPhase 4 (approved)SCN5A
LOPINAVIRChEMBLPhase 4 (approved)SCN5A
LURASIDONEChEMBLPhase 4 (approved)SCN5A
MEXILETINEChEMBLPhase 4 (approved)SCN5A
MIBEFRADILChEMBLPhase 4 (approved)SCN5A
MITOXANTRONEChEMBLPhase 4 (approved)SCN5A
MOXIFLOXACINChEMBLPhase 4 (approved)SCN5A
NEBIVOLOLChEMBLPhase 4 (approved)SCN5A
NELFINAVIRChEMBLPhase 4 (approved)SCN5A
NICARDIPINEChEMBLPhase 4 (approved)SCN5A
NIFEDIPINEChEMBLPhase 4 (approved)SCN5A
NIMODIPINEChEMBLPhase 4 (approved)SCN5A
NINTEDANIBChEMBLPhase 4 (approved)SCN5A
NISOLDIPINEChEMBLPhase 4 (approved)SCN5A
OLICERIDINEChEMBLPhase 4 (approved)SCN5A
PALONOSETRONChEMBLPhase 4 (approved)SCN5A
PAROXETINEChEMBLPhase 4 (approved)SCN5A
PHENYTOINChEMBLPhase 4 (approved)SCN5A
PIMOZIDEChEMBLPhase 4 (approved)SCN5A
PITOLISANTChEMBLPhase 4 (approved)SCN5A

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.2
BioBTree
v2.0.2

Sources 30

This page pulls from 30 datasets indexed by BioBTree:

chebichembl_activitychembl_moleculechembl_targetcivic_evidenceclingen_dosageclinical_trialsdepmapefoensemblentrezgogoparentgtopdbgtopdb_interactiongtopdb_ligandhgncmeshmondomsigdbpatent_compoundpharmgkbpharmgkb_guidelinepubchempubchem_activityreactomereactomeparentrefseqtranscriptuniprot